Custopharm, Inc.
http://www.custopharm.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Custopharm, Inc.
FTC’s Take On Two Pharma Mergers Shows Deals Can Clear Higher Hurdle
Pfizer’s acquisition of Arena without FTC intervention and Hikma’s acquisition of Custopharm with one product divestiture shows the commission is bound by anticompetitive facts of a deal. A more controversial merger may not get through, former FTC attorney says.
Hikma’s Injectables Business Expands As It Completes Custopharm Acquisition
Hikma has completed its acquisition of Custopharm, expanding its US injectables business as the company continues to look for more deals.
Hikma Gets FTC Nod For Custopharm Deal – But With Strings Attached
Hikma has moved closer to completing a deal worth more than $400m to acquire Custopharm, which promises to bolster its US injectables business. However, the FTC’s approval of the transaction comes with conditions.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- Other Names / Subsidiaries
-
- Hikma Pharmaceuticals plc